Amnog Early Benefit Assessment (EBA) in Germany - A Specific Challenge for Antidiabetics
Nov 1, 2016, 00:00
10.1016/j.jval.2016.09.1920
https://www.valueinhealthjournal.com/article/S1098-3015(16)33286-7/fulltext
Title :
Amnog Early Benefit Assessment (EBA) in Germany - A Specific Challenge for Antidiabetics
Citation :
https://www.valueinhealthjournal.com/action/showCitFormats?pii=S1098-3015(16)33286-7&doi=10.1016/j.jval.2016.09.1920
First page :
A680
Section Title :
Disease-Specific Studies
Open access? :
No
Section Order :
1814